Author Archives: Kate Hermans
For over three decades, Kate Hermans has spent her career successfully leading cross-functional teams to transform the growth of businesses ($0-1M, and up to $4B) with multiple successful exits. Currently, Ms. Hermans serves as Chair of Clue by BioWink, a Series C femtech company. She has been instrumental in helping the company achieve profitability, deliver robust growth, and successfully raise their Series C growth-capital round.
Ms. Hermans is also a member of the Board for Mid-Atlantic Diamond Ventures. Ms. Hermans is currently an Advisor to both early-stage (venture backed) and public biotech and healthtech companies. She is Founder and CEO of a stealth start-up, exploring the use of AI to support care partners of dementia patients. She is also an active speaker across multiple industry forums. Earlier, Ms. Hermans exited the Board of Ambrx Biopharma (AMAM), following Johnson & Johnson’s approximately $2B acquisition in 2024, having served as CEO in 2022 where she reset the company’s strategy, streamlined company operations and onboarded a new CEO. Previously Kate held various executive business leadership roles at 83bar, Radius Health, Bristol-Myers Squibb, Pfizer, Wyeth and Intel, working in the U.S., China, Africa, and globally.
